缺血性心臟病药物市场报告（按疾病类别、药物类别和地区）2025-2033

2024 年全球缺血性心臟病 (IHD) 药物市场规模达 66 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 93 亿美元，2025-2033 年期间的成长率 (CAGR) 为 3.73%。

缺血性心臟病 (IHD)，又称冠心病，是一种透过中断氧气和血液供应来损害心肌的疾病。它涉及血管分子变化或动脉粥状硬化导致冠状动脉突然闭塞和变窄。这种疾病通常以慢性胸痛和剧烈不适为特征，如果不及时治疗，可能会危及生命。根据病情的严重程度，治疗缺血性心臟病的药物种类繁多。例如，如果降胆固醇药物可以降低血液中的胆固醇水平，那么医生会开立阿斯匹灵来降低血液凝固倾向，并使用β受体阻断剂来降低心率和血压。治疗缺血性心臟病的药物还包括钙通道阻断剂和雷诺嗪，它们可以提高β受体阻断剂的疗效，并防止冠状动脉疾病进一步发展。

大众对介入性医疗程序日益增长的兴趣，以及抗心绞痛药物在治疗缺血性心臟病 (IHD) 中的广泛使用，是推动市场成长的关键因素之一。 IHD 药物正被纳入血管成形术、动脉粥状硬化斑块切除术和球囊血管成形术等心臟病治疗程序中，以确保患者健康康復并预防未来復发。此外，消费者对定期服用这些药物益处的认识不断提高，也对其需求产生了显着影响。过度饮酒、吸烟以及缺乏运动等生活习惯也导致心血管疾病的盛行率不断上升。此外，全球老年人口的不断增长，他们极易患心臟病，这也推动了对 IHD 药物的需求。

本报告回答的关键问题：

• 全球缺血性心臟病 (IHD) 药物市场迄今为止表现如何，未来几年将如何表现？
• COVID-19 对全球缺血性心臟病 (IHD) 药物市场有何影响？
• 根据疾病类别，市场是如何分類的？
• 根据药品类别，市场是如何分類的？
• 全球缺血性心臟病 (IHD) 药物产业的主要区域市场有哪些？
• 全球缺血性心臟病 (IHD) 药物产业价值链的各个阶段有哪些？
• 全球缺血性心臟病 (IHD) 药物产业的主要驱动因素和挑战是什么？
• 全球缺血性心臟病 (IHD) 药物产业的结构是怎么样的？主要参与者是谁？
• 全球缺血性心臟病（IHD）药物产业的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 次要来源
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：简介

• 概述
• 主要行业趋势

第五章：全球缺血性心臟病（IHD）药物市场

• 市场概览
• 市场表现
• COVID-19的影响
• 市场预测

第六章：市场细分：依疾病类别

• 心绞痛
• 心肌梗塞

第七章：市场区隔：依药品类别

• 抗血脂异常药物
• 钙通道阻断剂
• β受体阻断剂
• 血管紧张素转换酶抑制剂
• 血管张力素受体阻断剂
• 血管扩张剂
• 抗血栓药物

第八章：市场区隔：依地区

• 北美洲
• 欧洲
• 亚太地区
• 中东和非洲
• 拉丁美洲

第九章：SWOT分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

• 概述
• 买家的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第 12 章：价格分析

第 13 章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co.
  • Eisai Co., Ltd.

The global ischemic heart disease (IHD) drugs market size reached USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.3 Billion by 2033, exhibiting a growth rate (CAGR) of 3.73% during 2025-2033.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

Breakup by Disease Class:

• Angina Pectoris
• Myocardial Infarction

Breakup by Drug Class:

• Anti-Dyslipidemic Drugs
• Calcium Channel Blockers
• Beta-Blockers
• ACE Inhibitors
• ARBs
• Vasodilators
• Antithrombotic Agents

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

• How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
• What is the breakup of the market based on the disease class?
• What is the breakup of the market based on the drug class?
• What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
• What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
• What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
• What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
• What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Class

• 6.1 Angina Pectoris
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Infarction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Anti-Dyslipidemic Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Calcium Channel Blockers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Beta-Blockers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 ACE Inhibitors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 ARBs
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Vasodilators
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Antithrombotic Agents
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Bayer AG
  • 13.3.2 Eli Lilly and Company
  • 13.3.3 Novartis International AG
  • 13.3.4 Pfizer, Inc.
  • 13.3.5 Sanofi S.A.
  • 13.3.6 Actelion Pharmaceuticals Ltd.
  • 13.3.7 Baxter International Inc.
  • 13.3.8 Boehringer Ingelheim International GmbH
  • 13.3.9 Bristol-Myers Squibb Company
  • 13.3.10 Amgen Inc.
  • 13.3.11 F. Hoffmann-La Roche AG
  • 13.3.12 GlaxoSmithKline Plc
  • 13.3.13 Merck & Co.
  • 13.3.14 Eisai Co., Ltd.

List of Figures

• Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2024
• Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2024
• Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2024
• Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
• Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
• Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million USD), 2025-2033
• Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
• Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players